OligoCare (EORTC 1822-RP) is collecting evidence for best practice in the radical (radiation) treatment of oligometastatic disease, where the cancer has metastasized to a limited number of organs.
Despite its almost universal use, the level of evidence supporting radical local treatment in general for oligometastatic patients and stereotactic radiotherapy in particular is low. Uncertainties and variability in practice are therefore huge and it seems highly unlikely or even impossible that these issues will be solved within the traditional framework of prospective randomised trials.
OligoCare is a pragmatic observational cohort study to evaluate radical radiotherapy for patients with oligometastatic disease. The main objective is to identify patient, tumour, diagnostic and treatment characteristics impacting overall survival.
The first primary disease types to be studied are non-small cell lung cancer (NSCLC), breast cancer, prostate cancer and colorectal cancer.
ParticleCare (EORTC 1833-RP) aims to recruit all patients treated with particle therapy in particle centres throughout Europe and assess whether particle therapy leads to less clinical toxicity.
Particle therapy is a rapidly evolving technology with considerable potential in the treatment of cancer. ParticleCare aims to provide an effective data sharing platform for particle therapy and establish a uniform prospective data registration program for all patients treated with particle therapy in Europe.
This registry was initiated by the European Particle Therapy Network (EPTN), an ESTRO taskforce.
The objective of the ParticleCare cohort is to provide continuing evidence of the benefit of particle therapy at a European level for the most common tumour types. Almost all particle therapy facilities in Europe will participate in this cohort.
The first primary disease type to be studied is head & neck cancers. Others will be added as particle therapy use continues to spread.
ReCare (EORTC 2011-RP) will gather real-world data on patients treated with high-dose re-irradiation for local recurrence, new primary or secondary cancer. With the advent of modern radiotherapy techniques, high-dose re-radiotherapy is more frequently applied, although clinical evidence for its efficacy is scarce and data on safe dose constraints are practically non-existent, apart from very few exceptions.
Therefore, the currently available data does not allow firm assumptions on the safety and efficacy of high-dose re-irradiation, and cannot provide proper evidence to guide clinical practice and inform on consistent standards of care.
Within the current ReCare cohort, re-irradiation is considered with the following general assumptions:
“Re-irradiation” is defined as a therapeutic dose of radiation delivered to a region/organ which has previously received a therapeutic radiation dose where the summation of the first and the second course carries a risk of a clinical relevant morbidity.
“High-dose” is defined as re-irradiation to a minimum prescription dose equivalent to 50 Gy EQD2.
Submission of DICOM-RT plans from previous radiotherapy will be encouraged but not mandated. There are no restrictions regarding the techniques applied for re-irradiation treatment, i.e. EBRT, brachytherapy, particle therapy, etc. are all allowed.